Skystar Bio-Pharmaceutical Signs Multiple New Product and Distribution Contracts at the 2007 China Stock Breeding and Forage Industry Expo

XI'AN, China, June 18 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) ("Skystar" or "the Company"), a leading bio-pharmaceutical company in the People's Republic of China ("PRC"), today announced that it signed 15 new contracts valued at approximately $730,000 for year 2007, and successfully secured 20 Letter(s) of Intent with distributors.

Skystar secured these contracts during the 2007 China Stock Breeding and Forage Industry Expo in Ningbo, Zhejiang Province, which was held from May 18th - 20th, 2007. The Company obtained 15 product contracts which includes the company's leading vaccine, avian coccidiosis vaccine, existing Chinese herbal preparations and several newly launched products. A portion of the orders have already been delivered with the balance to be delivered by the end of June 2007. The new distributor contracts are expected to expand Skystar's geographic presence and deepen the company's penetration in its existing markets.

The expo, one of the largest in China's livestock and farming industry, is co-organized by the China Stock Breeding Association and China Forage Industry Association. Over 80,000 people attended the expo, where more than a thousand domestic and foreign companies and international organizations from over 20 countries and regions presented. Skystar's products highlighted at the exhibit included the avian coccidiosis vaccine and more than a dozen of the Company's new products including Chinese goldthread detoxification powder, kanamycin sulfate injection and thiamphenicol powder, which target a variety of diseases and symptoms in pigs, piglets and other animals including horses, cattle, sheep, rabbits and poultry.

"The China Stock Breeding and Forage Industry Expo is a major event, attracting our industry's leading brands, international organizations and customers. This event was a tremendous success for Skystar in marketing our products, enhancing our brand awareness and expanding our distribution network," commented Mr. Weibing Lu. "It also provided us with greater insight into the industry and product demand, which we will use to fine-tune our growth strategy."

Given Skystar's success at the China Stock Breeding and Forage Industry Expo, Skystar intends to continue presenting at high-profile trade shows throughout 2007 as the Company enhances its marketing efforts. Upcoming trade shows include the 19th Henan Province Poultry Trade Show organized by Henan Stock Breeding Bureau and Henan Poultry Industry Association from September 11th - 13th, and the 2007 Shandong Province Stock Breeding Expo organized by Shandong Stock Breeding Bureau and Shandong Stock Breeding Association from October 24th - 28th.

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The Company's product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The company recently completed construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to the Company's ability to accurately complete product orders, coordinate product design with its customers, ability to expand and grow its distribution channels, market acceptance of new products, competitive pressures, scale-up of manufacturing, political and economic factors in the People's Republic of China, the company's ability to find attractive acquisition candidates, dependence on a limited number of larger customers and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Skystar Bio-Pharmaceutical Co., Ltd.:

Scott Cramer

Director - U.S. Representative

Tel: +1-407-645-4433


CCG Elite Investor Relations:

Crocker Coulson, President


Leslie Richardson, Financial Writer

Tel: +1-310-231-8600 x122


Source: Skystar Bio-Pharmaceutical Co., Ltd.
Related Stocks: